RC18 160 mg ( DrugBank: - )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	1
53	Sjogren syndrome	1

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,342 /  Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03330418 (ClinicalTrials.gov)	January 29, 2018	31/10/2017	A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders	A Phase III Study of RC18, a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection for the Treatment of Subjects With Neuromyelitis Optica Spectrum Disorders.	Neuromyelitis Optica Spectrum Disorders	Biological: Placebo;Biological: RC18 160 mg	RemeGen Co., Ltd.	NULL	Recruiting	18 Years	65 Years	All	166	Phase 3	China

53. Sjogren syndrome

---

Clinical trials : 283 /  Drugs : 320 - (DrugBank : 101) / Drug target genes : 56 - Drug target pathways : 181

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04078386 (ClinicalTrials.gov)	November 21, 2019	18/7/2019	A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome	A Phase II Study of RC18, a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection for the Treatment of Subjects With Primary Sjögren's Syndrome	Primary Sjögren's Syndrome	Biological: Placebo;Biological: RC18 240 mg;Biological: RC18 160 mg	RemeGen Co., Ltd.	NULL	Completed	18 Years	65 Years	All	42	Phase 2	China